Followers | 155 |
Posts | 12584 |
Boards Moderated | 0 |
Alias Born | 12/29/2013 |
Monday, August 05, 2019 9:09:07 AM
8:30 AM ET 8/5/19 | Dow Jones
OTCQB Status and Accelerating Adoption
PHOENIX, Aug. 5, 2019 /PRNewswire/ -- Creative Medical Technology Holdings, Inc. (OTC: CELZ), a leading clinical-stage biotechnology company focused on Urology, Neurology and Orthopedics using stem cell treatments, today announced business updates regarding OTCQB status and plans for accelerating product adoption.
OTCQB Status:
-- Due to stock price dropping below the price required to maintain status,
the company has been moved from the OTCQB.
-- The company will continue to be a fully reporting company with PCAOB
accounting audits and timely filings with the SEC as required.
-- Our shareholders will still have the freedom of trading our stock with
complete insight to the company financials and operating activities.
Although the OTCQB is a highly desired status, we believe maintaining
fully audited public disclosures is the important component. This will
not change.
Key Activities to Drive Shareholder Value:
-- Launched new corporate website:
www.CreativeMedicalTechnology.com showcasing the full breadth of our
robust IP/product portfolio which we believe is best in the industry, bar
none.
-- Increased our marketing team and will continue to invest heavily to drive
awareness of our product portfolio across digital/social media with a
refresh of CaverStem(R) and FemCelz(R) websites launching soon.
-- Increasing the productivity of existing affiliated physicians and provide
new physicians with a more vibrant marketing package. By expanding the
education of our technologies to the physicians and patients we believe
that we will continue to gain more recognition as the preferred resource
to naturally enhance male (CaverStem(R)) and Female (FemCelz(R)) sexual
function and subsequently our degenerative disc (StemSpine(R)) technology,
amongst others in our portfolio.
-- Onboarding several new physicians in the months ahead thanks to the
success of our mailers and streamlined training process with multiple
facilities already in the cue.
-- Exhibiting at the A4M Regenerative Medicine Conference in December 2019.
Other conferences will be advised once commitments are confirmed.
-- Identify the correct strategic partner to commercialize the AmnioStem(R)
platform. There has been interest from various parties and all
opportunities will be considered.
-- Continue to expand our HIPAA compliant patient registry, wherein
physicians may share non-confidential data collected from participating
patients.
-- Completion of our clinical trial study report on CaverStem(R) and submit
for publication.
-- Continue to advance other patents in our portfolio.
-- Continue to increase cash flow.
We wish to congratulate Dr. Said and Dr. Bieri at Regenerative Medical Health in Las Cruces, NM who have received excellent media attention on ABC News and have announced the treatment of over 50 CaverStem(R) and FemCelz(R) patients in the past few months with a very high success rate.
"We have never been more confident in our company and the effectiveness of our stem cell portfolio and are grateful for our physician network that continues to treat patients utilizing our breakthrough Caverstem(R) and FemCelz(R) procedures," said Timothy Warbington, President and CEO of Creative Medical Technology Holdings Inc. "We also want to thank our shareholders that have stood by us and reaffirm our commitment to increasing shareholder value. We have taken a number of steps that we believe will help the world discover what we already know- regenerative medicine is the future of medicine and we will help lead the charge."
About Creative Medical Technology Holdings
Creative Medical Technology Holdings, Inc. is a commercial stage biotechnology company currently trading on the OTC under the ticker symbol CELZ. For further information about the company go to www.creativemedicaltechnology.com. For more information on our Caverstem(R) procedure please go to www.caverstem.com.
Forward-Looking Statements
OTC Markets has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming clinical trials and laboratory results, marketing efforts, funding, etc. Forward-looking statements address future events and conditions and, therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements. See the periodic and other reports filed by Creative Medical Technology Holdings, Inc. with the Securities and Exchange Commission and available on the Commission's website at www.sec.gov.
View original content to download multimedia:http://www.prnewswire.com/news-releases/creative-medical-technology-holdings-inc-august-2019-shareholder-update-300896248.html
SOURCE Creative Medical Technology Holdings, Inc.
/CONTACT: Timothy Warbington, CEO, 480-789-9939
/Web site: http://creativemedicaltechnology.com
> Dow Jones Newswires
August 05, 2019 08:30 ET (12:30 GMT)
Recent CELZ News
- Creative Medical Technology Holdings Announces Evolutionary Development of its iPSCelz® Program with the Successful Generation of iPSC Derived Islet Cells that Produce Human Insulin • GlobeNewswire Inc. • 06/24/2024 12:30:00 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 06/05/2024 08:05:11 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/17/2024 08:02:27 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/10/2024 08:45:39 PM
- Creative Medical Technology Holdings Provides Corporate Update • Business Wire • 03/27/2024 01:00:00 PM
- Creative Medical Technology Holdings Inc. Announces FDA Authorization for Groundbreaking Type 1 Diabetes Prevention Therapy Under Expanded Access • Business Wire • 03/07/2024 02:15:00 PM
- Biotech Finds Mid-Week Success Following FDA Announcement • AllPennyStocks.com • 03/06/2024 09:10:00 PM
- Creative Medical Technology Holdings, Inc. Receives FDA Orphan Drug Designation for CELZ-101 in Key Transplantation Therapy • Business Wire • 03/06/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/20/2023 09:05:37 PM
- Creative Medical Technology Holdings Provides Corporate Update • PR Newswire (US) • 11/15/2023 01:00:00 PM
- Creative Medical Technology Holdings Announces IRB Approval for FDA Cleared Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ ("CELZ-201-DDT") Novel Cell Therapy to Treat Chronic Lower Back Pain • PR Newswire (US) • 10/10/2023 12:00:00 PM
- Creative Medical Technology Holdings Receives FDA Clearance to Initiate a Phase 1/2 Clinical Trial of StemSpine® using AlloStem™ (CELZ-201-DDT) for the Treatment of Chronic Lower Back Pain • PR Newswire (US) • 09/19/2023 12:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2023 08:45:38 PM
Glidelogic Corp. Becomes TikTok Shop Partner, Opening a New Chapter in E-commerce Services • GDLG • Jul 5, 2024 7:09 AM
Freedom Holdings Corporate Update; Announces Management Has Signed Letter of Intent • FHLD • Jul 3, 2024 9:00 AM
EWRC's 21 Moves Gaming Studios Moves to SONY Pictures Studios and Green Lights Development of a Third Upcoming Game • EWRC • Jul 2, 2024 8:00 AM
BNCM and DELEX Healthcare Group Announce Strategic Merger to Drive Expansion and Growth • BNCM • Jul 2, 2024 7:19 AM
NUBURU Announces Upcoming TV Interview Featuring CEO Brian Knaley on Fox Business, Bloomberg TV, and Newsmax TV as Sponsored Programming • BURU • Jul 1, 2024 1:57 PM
Mass Megawatts Announces $220,500 Debt Cancellation Agreement to Improve Financing and Sales of a New Product to be Announced on July 11 • MMMW • Jun 28, 2024 7:30 AM